GSP Crop Science IPO opens for subscription on March 16, 2026, and closes on March 18, 2026, with an issue size of ₹240 crore comprising fresh issue of ₹240 crore equity shares for mainboard listing on March 24. Ahmedabad-based GSP Crop Science Ltd manufactures agrochemicals, technicals, and formulations including insecticides, fungicides, and herbicides serving domestic export markets since 1982. GSP Crop Science IPO proceeds fund debt repayment of ₹100 crore, working capital enhancement, and strategic expansion initiatives.
₹00
₹
₹
Expert Opinions
Market sentiment for GSP Crop Science IPO shows steady interest from agri-input investors, supported by established technical manufacturing capabilities despite commodity price cycle pressures. Company strengths include 507 product registrations, 89 granted patents contributing 20% sales, integrated technical-to-formulation chain, 40% export revenue diversification, and ₹1,152 crore FY24 topline stability.
Risks and challenges feature regulatory re-registration deadlines, raw material volatility impacting 60% costs, 35% debt/equity leverage requiring ₹200 crore repayment, customer concentration risks, and Chinese import competition eroding domestic pricing power. Valuation analysis of GSP Crop Science IPO and year 2025 reveals Return on Equity (ROE) of 18.38%, ROCE of 19.80%, and Net Asset Value (NAV) of ₹115.34, positioned at 25-30x P/E competitive versus UPL PI peers averaging 35x. Long-term investment perspective benefits from 10% crop protection CAGR through precision agriculture adoption and export market penetration.
Investor Considerations
GSP Crop Science IPO demonstrates stable company performance and fundamentals in FY25, maintaining ₹1,152 crore revenue through diversified agrochemical technicals and formulations across domestic export markets. Agrochemical sector outlook sustains 10% CAGR driven by precision farming adoption and export demand growth. IPO Valuation of Financial Year 2025 for GSP Crop Science IPO and year shows EBITDA Margin of 12.74%, PAT Margin of 6.26%, and Debt/Equity of 0.58, reflecting operational efficiency post ₹200 crore debt reduction.
Growth prospects leverage 507 product registrations, new technical manufacturing capacities, and 40% export revenue targeting expansion. Risk factors include regulatory re-registration deadlines, raw material price volatility affecting 60% costs, Chinese import competition, customer concentration pressures, and monsoon dependency. Short-term investment goals monitor listing stability amid commodity cycles, while long-term horizons capture sustained crop protection demand and innovation pipeline execution.
FAQs
GSP Crop Science IPO Current GMP is ₹00.
GSP Crop Science IPO Expected Returns is 0.00%.
GSP Crop Science IPO estimated listing price is ₹00.